½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1521392

¼¼°èÀÇ À̽ÄÇü ½ÉÀå ¸®µë °ü¸® ±â±â ½ÃÀå Á¶»ç º¸°í¼­ : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2024-2032³â)

Global Implantable Cardiac Rhythm Management Devices Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Value Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 124 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

À̽ÄÇü ½ÉÀå ¸®µë °ü¸® ±â±â ½ÃÀåÀÇ ¼¼°è ¼ö¿ä´Â 2023³â 150¾ï 7,000¸¸ ´Þ·¯¿¡¼­ 2032³â¿¡´Â 278¾ï 5,000¸¸ ´Þ·¯ °¡±î¿î ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, Á¶»ç ±â°£ÀÎ 2024-2032³â CAGRÀº 7.06%ÀÔ´Ï´Ù.

½ÉÀå ¸®µë °ü¸®(CRM) ±â±â¿¡´Â ºÎÁ¤¸ÆÀ̳ª ¼­¸Æ°ú °°Àº ½ÉÀå ¸®µë Àå¾Ö¸¦ ¸ð´ÏÅ͸µÇÏ°í °ü¸®Çϱâ À§ÇØ °í¾ÈµÈ ´Ù¾çÇÑ ÀÇ·á±â±â°¡ Æ÷ÇԵ˴ϴÙ. ÀÌ·¯ÇÑ Àåºñ´Â ¿Ü°úÀûÀ¸·Î ü³»¿¡ ÀÌ½ÄµÇ¾î ½ÉÀåÀÇ Àü±âÀû È°µ¿À» Á¶ÀýÇÏ°í ÀûÀýÇÑ ½É¹Ú¼ö¿Í ¸®µëÀ» º¸ÀåÇϱâ À§ÇØ ±â´ÉÇÕ´Ï´Ù. À̽ÄÇü ½ÉÀå ¸®µë °ü¸® ±â±â¿¡´Â ½ÉÀåÀ» ÀÚ±ØÇÏ´Â Àü±â ÀÚ±ØÀ» °ø±ÞÇÏ¿© ¼­¸ÆÀ» Ä¡·áÇÏ´Â ½É¹Ú Á¶À²±â, ½ÉÀå ¸®µëÀ» ¸ð´ÏÅ͸µÇÏ°í ÇÊ¿ä¿¡ µû¶ó Ãæ°ÝÀ̳ª ÆäÀ̽ÌÀ» °ø±ÞÇÏ¿© °©ÀÛ½º·¯¿î ½ÉÀå ¸¶ºñ¸¦ ¿¹¹æÇÏ´Â À̽ÄÇü Á¦¼¼µ¿±â(ICD) µîÀÌ ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

¼¼°èÀûÀÎ °í·ÉÈ­¿Í ½ÉÇ÷°ü Áúȯ Áõ°¡·Î ÀÎÇØ À̽ÄÇü ½ÉÀå ¸®µë °ü¸® ±â±â¸¦ ÇÊ¿ä·Î Çϴ ȯÀÚÃþÀÌ Å©°Ô È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Àα¸ Åë°èÇÐÀû º¯È­·Î ÀÎÇØ ½ÉÀå ¸®µëÀ» È¿°úÀûÀ¸·Î ¸ð´ÏÅ͸µÇÏ°í Á¶ÀýÇÏ¿© ºÎÁ¤¸ÆÀ¸·Î ÀÎÇÑ »ç¸Á·üÀ» ³·Ãß´Â À̽ÄÇü Àåºñ¿¡ ´ëÇÑ Çʿ伺ÀÌ Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù. ±â¼ú ¹× Àåºñ ¼º´ÉÀÇ ¹ßÀüÀÌ ½ÃÀå È®´ëÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ±â±â ¼ÒÇüÈ­, ¹èÅ͸® ¼ö¸í ¿¬Àå, Áø´Ü ±â´É °­È­, ¿ø°Ý ¸ð´ÏÅ͸µ ½Ã½ºÅÛ°úÀÇ È£È¯¼º µî ±â¼ú Çõ½ÅÀº ±â±âÀÇ È¿°ú¿Í ȯÀÚ ¿¹Èĸ¦ °³¼±ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú ¹ßÀüÀº ÀåºñÀÇ ¼º´ÉÀ» Çâ»ó½ÃÄÑ È¯ÀÚÀÇ ÆíÀǼº°ú Ä¡·á ¼øÀÀµµ¸¦ ³ôÀÌ´Â µ¥ ±â¿©ÇÕ´Ï´Ù. ¶ÇÇÑ ¿¹¹æÀû °Ç°­°ü¸® ¹× Àû±ØÀûÀÎ ¸¸¼ºÁúȯ °ü¸®ÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÔ¿¡ µû¶ó À̽ÄÇü ½ÉÀ帮µë °ü¸® ±â±âÀÇ ¼ºÀåµµ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ÀÇ·áÁø°ú ȯÀÚµé »çÀÌ¿¡¼­ ½ÉÀå ¸®µë Àå¾ÖÀÇ Á¶±â Áø´Ü°ú Á¶±â °³ÀÔÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó À̽ÄÇü CRM ±â±â »ç¿ë·üÀÌ Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù. ±×·¯³ª À̽ÄÇü ½ÉÀå ¸®µë °ü¸® ±â±â ½ÃÀåÀÇ ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î´Â Àåºñ ÀÌ½Ä ¹× Á¤ºñ¿Í °ü·ÃµÈ ³ôÀº ºñ¿ë°ú À̽ÄÇü ÀåºñÀÇ Ãʱ⠺ñ¿ëÀÌ ²ÅÈü´Ï´Ù.

ÀÌ Á¶»ç ¸®Æ÷Æ®´Â Porter's Five Forces ¸ðµ¨, ½ÃÀåÀÇ ¸Å·Â ºÐ¼®, ¹ë·ùüÀÎ ºÐ¼®À» Ä¿¹öÇÏ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÅøÀº ¾÷°èÀÇ ±¸Á¶¸¦ ¸íÈ®ÇÏ°Ô ÆľÇÇÏ°í, ¼¼°è ·¹º§¿¡¼­ÀÇ °æÀï ¸Å·ÂÀ» Æò°¡Çϴµ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ ÅøÀº ¼¼°èÀÇ À̽ÄÇü ½ÉÀå ¸®µë °ü¸® ±â±â ½ÃÀåÀÇ °¢ ºÎ¹®À» Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼öµµ ÀÖ½À´Ï´Ù. À̽ÄÇü ½ÉÀå ¸®µë °ü¸® ±â±â »ê¾÷ÀÇ ¼ºÀå°ú µ¿ÇâÀº ÀÌ Á¶»ç¿¡ ÀüüÀûÀÎ ¾îÇÁ·ÎÄ¡¸¦ Á¦°øÇÕ´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­

À̽ÄÇü ½ÉÀå ¸®µë °ü¸® ±â±â ½ÃÀå º¸°í¼­¿¡¼­´Â ±¹°¡º° ¹× Áö¿ªº° ºÎ¹®¿¡ °üÇÑ »ó¼¼ µ¥ÀÌÅ͸¦ Á¦°øÇϸç, ÀÌ¿¡ µû¶ó Àü·«°¡°¡ ÇâÈÄ ºñÁö´Ï½º ±âȸ¿Í ÇÔ²² °¢°¢ÀÇ Á¦Ç° ¹× ¼­ºñ½ºÀÇ Å¸±êÃþÀ» ½Äº°Çϴµ¥ µµ¿òÀÌ µË´Ï´Ù.

Á¦Ç°º°

  • ÆäÀ̽º¸ÞÀÌÄ¿(±âÁ¸Çü ÆäÀ̽º¸ÞÀÌÄ¿, ¸®µå¸®½º ÆäÀ̽º¸ÞÀÌÄ¿)
  • ICD(½Ì±Û è¹ö ICD, µà¾ó è¹ö ICD)
  • CRT(CRT Á¦¼¼µ¿±â, CRT ÆäÀ̽º¸ÞÀÌÄ¿)

ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø
  • ½ÉÀå Àü¹® ¼¾ÅÍ
  • ±âŸ

Áö¿ª ºÐ¼®

ÀÌ ¼½¼Ç¿¡¼­´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ & ¾ÆÇÁ¸®Ä« À̽ÄÇü ½ÉÀå ¸®µë °ü¸® ±â±â ½ÃÀåÀÇ ÇöÀç ¹× ÇâÈÄ ¼ö¿ä¸¦ °­Á¶ÇÏ´Â Áö¿ª Àü¸ÁÀ» ´Ù·ç°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ º» ¸®Æ÷Æ®´Â ¸ðµç ÁÖ¿ä Áö¿ª¿¡¼­ °³º° ¾ÖÇø®ÄÉÀÌ¼Ç ºÎ¹®ÀÇ ¼ö¿ä, ÃßÁ¤¡¤¿¹Ãø¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù.

Ä¿½ºÅÒ ¿ä°ÇÀÌ ÀÖ´Â °æ¿ì, ¹®ÀÇÇØÁֽñ⠹ٶø´Ï´Ù. ´ç»çÀÇ Á¶»ç ÆÀÀÌ °í°´ÀÇ ¿ä±¸¿¡ µû¶ó ¸ÂÃãÇü º¸°í¼­¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå °³¿ä

  • ½ÃÀåÀÇ ÇÏÀ̶óÀÌÆ®
  • ¼¼°è ½ÃÀå ÇöȲ

Á¦3Àå À̽ÄÇü ½ÉÀå ¸®µë °ü¸® ±â±â - »ê¾÷ ºÐ¼®

  • ¼­·Ð : ½ÃÀå ¿ªÇÐ
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ½ÃÀå ±âȸ
  • ¾÷°è µ¿Çâ
  • Porter's Five Forces ºÐ¼®
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼®

Á¦4Àå ¹ë·ùüÀÎ ºÐ¼®

  • ¹ë·ùüÀÎ ºÐ¼®
  • ¿øÀç·á ºÐ¼®
    • ¿øÀç·á ¸®½ºÆ®
    • ¿øÀç·á Á¦Á¶¾÷ü ¸®½ºÆ®
    • ÁÖ¿ä ¿øÀç·áÀÇ °¡°Ý µ¿Çâ
  • ÀáÀçÀû ¹ÙÀÌ¾î ¸®½ºÆ®
  • ¸¶ÄÉÆà ä³Î
    • ´ÙÀÌ·ºÆ® ¸¶ÄÉÆÃ
    • ÀδÙÀÌ·ºÆ® ¸¶ÄÉÆÃ
    • ¸¶ÄÉÆà ä³Î ¹ßÀü µ¿Çâ

Á¦5Àå ¼¼°èÀÇ À̽ÄÇü ½ÉÀå ¸®µë °ü¸® ±â±â ½ÃÀå ºÐ¼® : Á¦Ç°º°

  • Á¦Ç°º° °³¿ä
  • Á¦Ç°º° °ú°Å ¹× ¿¹Ãø µ¥ÀÌÅÍ ºÐ¼®
  • ÆäÀ̽º¸ÞÀÌÄ¿(±âÁ¸Çü ÆäÀ̽º¸ÞÀÌÄ¿, ¸®µå¸®½º ÆäÀ̽º¸ÞÀÌÄ¿)
  • ICD(½Ì±Û è¹ö ICD, µà¾ó è¹ö ICD)
  • CRT(CRT Á¦¼¼µ¿±â, CRT ÆäÀ̽º¸ÞÀÌÄ¿)

Á¦6Àå ¼¼°èÀÇ À̽ÄÇü ½ÉÀå ¸®µë °ü¸® ±â±â ½ÃÀå ºÐ¼® : ÃÖÁ¾ ¿ëµµº°

  • ÃÖÁ¾ ¿ëµµº° °³¿ä
  • ÃÖÁ¾ ¿ëµµº° °ú°Å ¹× ¿¹Ãø µ¥ÀÌÅÍ ºÐ¼®
  • º´¿ø
  • ½ÉÀå Àü¹® ¼¾ÅÍ
  • ±âŸ

Á¦7Àå ¼¼°èÀÇ À̽ÄÇü ½ÉÀå ¸®µë °ü¸® ±â±â ½ÃÀå ºÐ¼® : Áö¿ªº°

  • Áö¿ªº° Àü¸Á
  • ¼­·Ð
  • ºÏ¹Ì ÆǸŠºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ºÏ¹Ì : ºÎ¹®º°
    • ºÏ¹Ì ±¹°¡º°
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´ ÆǸŠºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • À¯·´ ºÎ¹®º°
    • À¯·´ ±¹°¡º°
    • ¿µ±¹
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ·¯½Ã¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç ÆǸŠºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ¾Æ½Ã¾ÆÅÂÆò¾ç ºÎ¹®º°
    • ¾Æ½Ã¾ÆÅÂÆò¾ç ±¹°¡º°
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • È£ÁÖ
    • µ¿³²¾Æ½Ã¾Æ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä« ÆǸŠºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ¶óƾ¾Æ¸Þ¸®Ä« ºÎ¹®º°
    • ¶óƾ¾Æ¸Þ¸®Ä« ±¹°¡º°
    • ºê¶óÁú
    • ¾Æ¸£ÇîƼ³ª
    • Æä·ç
    • Ä¥·¹
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ÆǸŠºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ºÎ¹®º°
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ±¹°¡º° ¸®½ºÆ®
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • À̽º¶ó¿¤
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦8Àå À̽ÄÇü ½ÉÀå ¸®µë °ü¸® ±â±â ±â¾÷ °æÀï ±¸µµ

  • À̽ÄÇü ½ÉÀå ¸®µë °ü¸® ±â±â ½ÃÀåÀÇ °æÀï
  • ÆÄÆ®³Ê½Ê/Á¦ÈÞ/ÇÕÀÇ
  • ÇÕº´¡¤Àμö
  • ½ÅÁ¦Ç° ¹ß¸Å
  • ±âŸ °³¹ß

Á¦9Àå ±â¾÷ °³¿ä

  • »óÀ§ ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®
  • ½ÃÀå ÁýÁßµµ
  • Medtronic
  • Abbott
  • Boston Scientific Corporation
  • Koninklijke Philips N.V.
  • Zoll Medical Corporation
  • Biotronik
  • Stryker
  • Schiller AG
  • Nihon Kohden Corporation
  • Microport Scientific Corporation
KSA 24.08.01

The global demand for Implantable Cardiac Rhythm Management Devices Market is presumed to reach the market size of nearly USD 27.85 Billion by 2032 from USD 15.07 Billion in 2023 with a CAGR of 7.06% under the study period 2024-2032.

Implantable cardiac rhythm management (CRM) devices encompass a range of medical devices designed to monitor and manage heart rhythm disorders, such as arrhythmias & bradycardia. These devices are surgically implanted within the body and function to regulate the heart's electrical activity, ensuring appropriate heart rate and rhythm. Implantable cardiac rhythm management devices include pacemakers for treating bradycardia by delivering electrical impulses to stimulate the heart and implantable cardioverter-defibrillators (ICDs) that monitor heart rhythms and deliver shocks or pacing as needed to prevent sudden cardiac arrest.

MARKET DYNAMICS

An aging population globally, coupled with the increasing prevalence of cardiovascular diseases, is significantly expanding the patient pool, requiring implantable cardiac rhythm management devices. This demographic shift highlights the growing need for implantable devices that can effectively monitor and regulate heart rhythms, thereby reducing mortality rates associated with cardiac arrhythmias. Advancements in technology and device capabilities are driving market expansion. Innovations such as miniaturization of devices, longer battery life, enhanced diagnostic features, and compatibility with remote monitoring systems improve device efficacy and patient outcomes. These technological advancements enhance device performance and contribute to patient convenience and compliance with therapy. Moreover, the rising adoption of preventive healthcare measures and proactive chronic disease management are fuelling the growth of implantable cardiac rhythm management devices. Rising awareness among healthcare providers & patients about the benefits of early diagnosis and intervention for cardiac rhythm disorders drives higher utilization of implantable CRM devices. However, the high costs associated with device implantation and maintenance and the initial expense of implantable devices, pose hinder the implantable cardiac rhythm management devices market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Implantable Cardiac Rhythm Management Devices. The growth and trends of Implantable Cardiac Rhythm Management Devices industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Implantable Cardiac Rhythm Management Devices market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

  • Pacemaker (Conventional Pacemakers, Leadless Pacemaker)
  • ICDs (Single Chamber ICDs, Dual Chamber ICDs)
  • CRT (CRT-Defibrillator, CRT-Pacemaker)

By End-Use

  • Hospitals
  • Specialty Cardiac Centers
  • Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Implantable Cardiac Rhythm Management Devices market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Implantable Cardiac Rhythm Management Devices market include Medtronic, Abbott, Boston Scientific Corporation, Koninklijke Philips N.V., Zoll Medical Corporation, Biotronik, Stryker, Schiller AG, Nihon Kohden Corporation, Microport Scientific Corporation. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Product
    • 3.7.2 Market Attractiveness Analysis By End-Use
    • 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET ANALYSIS BY PRODUCT

  • 5.1. Overview By Product
  • 5.2. Historical and Forecast Data Analysis By Product
  • 5.3. Pacemaker (Conventional Pacemakers, Leadless Pacemaker) Historic and Forecast Sales By Regions
  • 5.4. ICDs (Single Chamber ICDs, Dual Chamber ICDs) Historic and Forecast Sales By Regions
  • 5.5. CRT (CRT-Defibrillator, CRT-Pacemaker) Historic and Forecast Sales By Regions

6. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET ANALYSIS BY END-USE

  • 6.1. Overview By End-Use
  • 6.2. Historical and Forecast Data Analysis By End-Use
  • 6.3. Hospitals Historic and Forecast Sales By Regions
  • 6.4. Specialty Cardiac Centers Historic and Forecast Sales By Regions
  • 6.5. Others Historic and Forecast Sales By Regions

7. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET ANALYSIS BY GEOGRAPHY

  • 7.1. Regional Outlook
  • 7.2. Introduction
  • 7.3. North America Sales Analysis
    • 7.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.3.2 North America By Segment Sales Analysis
    • 7.3.3 North America By Country Sales Analysis
    • 7.3.4 United States Sales Analysis
    • 7.3.5 Canada Sales Analysis
    • 7.3.6 Mexico Sales Analysis
  • 7.4. Europe Sales Analysis
    • 7.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.4.2 Europe By Segment Sales Analysis
    • 7.4.3 Europe By Country Sales Analysis
    • 7.4.4 United Kingdom Sales Analysis
    • 7.4.5 France Sales Analysis
    • 7.4.6 Germany Sales Analysis
    • 7.4.7 Italy Sales Analysis
    • 7.4.8 Russia Sales Analysis
    • 7.4.9 Rest Of Europe Sales Analysis
  • 7.5. Asia Pacific Sales Analysis
    • 7.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.5.2 Asia Pacific By Segment Sales Analysis
    • 7.5.3 Asia Pacific By Country Sales Analysis
    • 7.5.4 China Sales Analysis
    • 7.5.5 India Sales Analysis
    • 7.5.6 Japan Sales Analysis
    • 7.5.7 South Korea Sales Analysis
    • 7.5.8 Australia Sales Analysis
    • 7.5.9 South East Asia Sales Analysis
    • 7.5.10 Rest Of Asia Pacific Sales Analysis
  • 7.6. Latin America Sales Analysis
    • 7.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.6.2 Latin America By Segment Sales Analysis
    • 7.6.3 Latin America By Country Sales Analysis
    • 7.6.4 Brazil Sales Analysis
    • 7.6.5 Argentina Sales Analysis
    • 7.6.6 Peru Sales Analysis
    • 7.6.7 Chile Sales Analysis
    • 7.6.8 Rest of Latin America Sales Analysis
  • 7.7. Middle East & Africa Sales Analysis
    • 7.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.7.2 Middle East & Africa By Segment Sales Analysis
    • 7.7.3 Middle East & Africa By Country Sales Analysis
    • 7.7.4 Saudi Arabia Sales Analysis
    • 7.7.5 UAE Sales Analysis
    • 7.7.6 Israel Sales Analysis
    • 7.7.7 South Africa Sales Analysis
    • 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES COMPANIES

  • 8.1. Implantable Cardiac Rhythm Management Devices Market Competition
  • 8.2. Partnership/Collaboration/Agreement
  • 8.3. Merger And Acquisitions
  • 8.4. New Product Launch
  • 8.5. Other Developments

9. COMPANY PROFILES OF IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Market Concentration Rate
  • 9.3. Medtronic
    • 9.3.1 Company Overview
    • 9.3.2 Company Revenue
    • 9.3.3 Products
    • 9.3.4 Recent Developments
  • 9.4. Abbott
    • 9.4.1 Company Overview
    • 9.4.2 Company Revenue
    • 9.4.3 Products
    • 9.4.4 Recent Developments
  • 9.5. Boston Scientific Corporation
    • 9.5.1 Company Overview
    • 9.5.2 Company Revenue
    • 9.5.3 Products
    • 9.5.4 Recent Developments
  • 9.6. Koninklijke Philips N.V.
    • 9.6.1 Company Overview
    • 9.6.2 Company Revenue
    • 9.6.3 Products
    • 9.6.4 Recent Developments
  • 9.7. Zoll Medical Corporation
    • 9.7.1 Company Overview
    • 9.7.2 Company Revenue
    • 9.7.3 Products
    • 9.7.4 Recent Developments
  • 9.8. Biotronik
    • 9.8.1 Company Overview
    • 9.8.2 Company Revenue
    • 9.8.3 Products
    • 9.8.4 Recent Developments
  • 9.9. Stryker
    • 9.9.1 Company Overview
    • 9.9.2 Company Revenue
    • 9.9.3 Products
    • 9.9.4 Recent Developments
  • 9.10. Schiller AG
    • 9.10.1 Company Overview
    • 9.10.2 Company Revenue
    • 9.10.3 Products
    • 9.10.4 Recent Developments
  • 9.11. Nihon Kohden Corporation
    • 9.11.1 Company Overview
    • 9.11.2 Company Revenue
    • 9.11.3 Products
    • 9.11.4 Recent Developments
  • 9.12. Microport Scientific Corporation
    • 9.12.1 Company Overview
    • 9.12.2 Company Revenue
    • 9.12.3 Products
    • 9.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦